Transgenic avian-derived recombinant human interferon-α2b (AVI-005) in healthy subjects: An open-label, single-dose, controlled study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 3, 2007, Pages 161-168

  Patel, T B ^a   Pequignot, E ^a   Parker, S H ^b   Leavitt, M C ^b   Greenberg, H E ^a   Kraft, Walter K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Avigenics   (United States)

Author keywords

2 5 oligoadenylate synthetase; Hepatitis C; Interferon inducible protein kinase; Interferon 2b; Neopterin; Pharmacokinetics; 2 microglobulin

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; AVI 005; BETA 2 MICROGLOBULIN; MESSENGER RNA; NEOPTERIN; PROTEIN KINASE R; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN EXPERIMENT; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 33947259007     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp45161     Document Type: Article

References (17)

1. Aurisicchio L, Delmastro P, Salucci V, Paz OG, Rovere P, Ciliberto G, La Monica N et al. Liver-specific alpha2 interferon gene expression results in protection from induced hepatitis. J Virol. 2000; 74: 4816-4823.
2. Balkwill FR. Interferons. Lancet. 1989; 1: 1060-1063.
3. CDC Web Site for Hepatitis C Viral Information. http://www.cdc.gov/ ncidod/disases/hepatitis/c/plan/HCV_infection.htm, Last accessed January 12, 2007.
4. Corssmit EP, Heyligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol. 1997; 107: 359-363.
5. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today. 1988; 9: 150-155.
6. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004; 350: 1118-1129.
7. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatitis C intervention therapy group. Clin Pharmacol Ther. 2000; 68: 556-567.
8. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-2695.
9. Li S, Nagai K, Koromilas AE. A diminished activation capacity of the interferon-inducible protein kinase PKR in human T lymphocytes. Eur J Biochem. 2000; 267: 1598-1606.
10. Merritt JA, Ball LA, Sielaff KM, Meltzer DM, Borden EC. Modulation of 2′,5′-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration. J Interferon Res. 1986; 6: 189-198.
11. Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther. 1996; 59: 636-646.
12. Remes K, Tienhaara A, Pelliniemi TT. Effects of alpha-interferon on serum beta-2-microglobulin. Leuk Lymphoma. 1996; 21: 233-238.
13. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001; 14: 778-809.
14. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
15. 2a as a function of dose and route of administration in healthy volunteers. Clin Pharmacol Ther. 1987; 42: 567-575.
16. World Health Organization Web Site for Hepatitis C. http://www.who.int/ mediacentre/factsheets/fs164/en/, Last accessed February 15, 2006.
17. Zheng X, Bevilacqua PC. Activation of the protein kinase PKR by short double-stranded RNAs with single-stranded tails. RNA 2004; 10: 1934-1945.